Bregal Sagemount

Gene Yoon serves as Managing Partner and leads the firm's investment committee. He is supported by senior partners including Blair Greenberg, who co-heads the credit practice, Daniel Kim, who oversees software investments, and Pavan Nigam, who leads healthcare. The firm operates with a partnership model where sector heads drive origination and execution within their verticals.

Sagemount is an independent partnership within Bregal Investments, the private equity platform of the Brenninkmeijer family. Bregal provides permanent, evergreen capital to Sagemount's vehicles, which means the firm does not need to return commitments on a standard fund-cycle schedule. Sagemount's leadership team manages all investment decisions and portfolio operations autonomously.

The firm writes equity checks ranging from $20 million to $200 million and can deploy across common stock, preferred equity, convertible notes, and multiple credit instruments including first-lien, second-lien, and unitranche loans. This blended capital approach allows Sagemount to structure minority growth investments, majority recapitalizations, and non-dilutive credit facilities within the same relationship.

Sagemount invests directly into operating companies and does not operate as a fund-of-funds. The firm has occasionally co-invested alongside other growth-equity managers, but its core model is originating and leading its own transactions. It does not publicly participate in LP commitments to external managers.

Sagemount targets growth-stage companies with proven product-market fit and scalable revenue — typically $10 million to $100 million in annual recurring revenue for software businesses, or comparable scale in healthcare and services. The firm avoids seed and early-stage venture but will occasionally invest in late-stage pre-IPO rounds, as it did with Zuora before its public offering.

Sagemount does not invest in deep biotechnology, medical devices requiring FDA clinical trials, traditional fossil-fuel extraction, or pre-revenue life sciences. The firm's healthcare exposure centers on technology-enabled services, digital health platforms, and healthcare IT rather than therapeutics or diagnostics.

The capital originates from the Brenninkmeijer family, whose wealth was built through the C&A retail empire founded in 1841. Bregal Investments serves as the family's private equity platform, deploying institutional-scale commitments into multiple strategies including Sagemount's growth-equity vehicles. The family's permanent capital base is the structural backbone of Sagemount's longer-duration investment approach.